These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 24865118

  • 1. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab.
    Berglund A, Willén L, Grödeberg L, Skattum L, Hagberg H, Pauksens K.
    Acta Oncol; 2014 Sep; 53(9):1212-20. PubMed ID: 24865118
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.
    Vaccine; 2010 Feb 17; 28(7):1740-5. PubMed ID: 20034605
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G, Horváth P, Muth L, Sólyom A, Garami M, Kovács G, Nyári T, Molnár D, Pauler G, Jankovics I.
    Pediatr Blood Cancer; 2014 Jun 17; 61(6):1013-6. PubMed ID: 24395342
    [Abstract] [Full Text] [Related]

  • 4. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H, Wenisch JM, Tobudic S, Gualdoni GA, Rödler S, Rasoul-Rockenschaub S, Jaksch P, Redlberger-Fritz M, Popow-Kraupp T, Burgmann H.
    Vaccine; 2011 Sep 16; 29(40):6888-93. PubMed ID: 21803100
    [Abstract] [Full Text] [Related]

  • 5. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.
    Vaccine; 2012 Jun 22; 30(30):4543-51. PubMed ID: 22475864
    [Abstract] [Full Text] [Related]

  • 6. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, Ranghiero A, Cecconi G, Zanetti AR.
    Vaccine; 2011 Nov 15; 29(49):9209-13. PubMed ID: 21974995
    [Abstract] [Full Text] [Related]

  • 7. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
    Chang YT, Guo CY, Tsai MS, Cheng YY, Lin MT, Chen CH, Shen D, Wang JR, Sung JM.
    Vaccine; 2012 Jul 13; 30(33):5009-18. PubMed ID: 22658967
    [Abstract] [Full Text] [Related]

  • 8. [Simultaneous vaccination against influenza and invasive pneumococcal disease in chronic dialysis patients].
    Trmal J, Havlícková M, Bícová R, Bitterová Z, Kelerová J.
    Epidemiol Mikrobiol Imunol; 2005 Aug 13; 54(3):123-8. PubMed ID: 16173523
    [Abstract] [Full Text] [Related]

  • 9. Adjuvanted influenza a (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy-treated patients.
    Cherif H, Höglund M, Pauksens K.
    Eur J Haematol; 2013 May 13; 90(5):413-9. PubMed ID: 23444982
    [Abstract] [Full Text] [Related]

  • 10. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, Sauvageau C, Dionne M, Gilca R, Skowronski D.
    Vaccine; 2011 Dec 09; 30(1):35-41. PubMed ID: 22063386
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
    Nakashima K, Aoshima M, Ohfuji S, Yamawaki S, Nemoto M, Hasegawa S, Noma S, Misawa M, Hosokawa N, Yaegashi M, Otsuka Y.
    Hum Vaccin Immunother; 2018 Dec 09; 14(8):1923-1930. PubMed ID: 29561248
    [Abstract] [Full Text] [Related]

  • 12. Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.
    Lagler H, Tobudic S, Ramharter M, Elandt K, Sperr WR, Redlberger-Fritz M, Popow-Kraupp T, Jäger U, Zielinski CC, Burgmann H.
    Vaccine; 2012 Nov 06; 30(48):6864-70. PubMed ID: 22989690
    [Abstract] [Full Text] [Related]

  • 13. Prevention of mortality and pneumonia among nursing home older adults by dual pneumococcal and seasonal influenza vaccination during a pandemic caused by novel pandemic influenza A (H1N1).
    Chan TC, Hung IF, Luk JK, Shea YF, Chan FH, Woo PC, Chu LW.
    J Am Med Dir Assoc; 2012 Oct 06; 13(8):698-703. PubMed ID: 22722051
    [Abstract] [Full Text] [Related]

  • 14. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years.
    Saitoh A, Nagai A, Tenjinbaru K, Li P, Vaughn DW, Roman F, Kato T.
    Hum Vaccin Immunother; 2012 Jun 06; 8(6):749-58. PubMed ID: 22495117
    [Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T, Forstén A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F.
    Vaccine; 2012 Feb 08; 30(7):1388-96. PubMed ID: 22192847
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
    Tremblay CL, Rouleau D, Fortin C, Toma E, Sylla M, Cyr L, Cote S, Baz M, Sampalis J, Trautman L, Sékaly RP, Boivin G.
    Vaccine; 2011 Feb 04; 29(7):1359-63. PubMed ID: 21185423
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
    Hakim H, Allison KJ, Van De Velde LA, Li Y, Flynn PM, McCullers JA.
    Vaccine; 2012 Jan 20; 30(5):879-85. PubMed ID: 22155630
    [Abstract] [Full Text] [Related]

  • 18. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G.
    Vaccine; 2012 May 14; 30(23):3470-7. PubMed ID: 22446638
    [Abstract] [Full Text] [Related]

  • 19. Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial.
    Uno S, Kimachi K, Kei J, Miyazaki K, Oohama A, Nishimura T, Ibaragi K, Odoh K, Kudo Y, Kino Y.
    Microbiol Immunol; 2011 Nov 14; 55(11):783-9. PubMed ID: 21895745
    [Abstract] [Full Text] [Related]

  • 20. Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.
    Maruszak H, Jeganathan S, Smith DE, Robertson P, Barnes T, Furner V.
    HIV Med; 2012 Jul 14; 13(6):352-7. PubMed ID: 22296264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.